Get the Stockscreener App
192.54
0.76%
1.45
Pre-market:
192.53
-0.010
-0.01%
Iqvia Holdings Inc stock is traded at $192.54, with a volume of 1.34M.
It is up +0.76% in the last 24 hours and up +19.87% over the past month.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
See More
Previous Close:
$191.09
Open:
$191.73
24h Volume:
1.34M
Relative Volume:
0.61
Market Cap:
$32.73B
Revenue:
$15.70B
Net Income/Loss:
$1.24B
P/E Ratio:
27.86
EPS:
6.91
Net Cash Flow:
$2.01B
1W Performance:
+6.91%
1M Performance:
+19.87%
6M Performance:
-0.32%
1Y Performance:
-19.65%
1-Day Range:
$190.32
$193.59
1-Week Range:
$179.59
$193.59
52-Week Range:
$134.65
$252.88
Iqvia Holdings Inc Stock (IQV) Company Profile
Name
Iqvia Holdings Inc
Sector
Industry
Phone
919-998-2000
Address
2400 ELLIS ROAD, DURHAM, NC
Compare IQV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IQV
Iqvia Holdings Inc
|
192.54 | 32.49B | 15.70B | 1.24B | 2.01B | 6.91 |
|
TMO
Thermo Fisher Scientific Inc
|
487.54 | 184.66B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
209.01 | 151.04B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
637.86 | 52.07B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
118.15 | 33.86B | 6.63B | 1.17B | 1.19B | 4.05 |
Iqvia Holdings Inc Stock (IQV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-03-25 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-20-24 | Initiated | Stephens | Overweight |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Sep-04-24 | Initiated | RBC Capital Mkts | Outperform |
| Jul-24-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-13-24 | Initiated | BTIG Research | Buy |
| Nov-02-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Mar-17-23 | Initiated | Truist | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Nov-17-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jul-15-22 | Initiated | SVB Leerink | Outperform |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-29-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-16-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Mar-08-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jul-07-20 | Initiated | Stephens | Equal-Weight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Upgrade | CFRA | Sell → Hold |
| Nov-14-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-21-19 | Upgrade | Mizuho | Neutral → Buy |
| May-28-19 | Initiated | SVB Leerink | Outperform |
| Jan-18-19 | Upgrade | Jefferies | Hold → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Oct-02-18 | Reiterated | Robert W. Baird | Outperform |
| Jul-25-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-25-18 | Reiterated | Stifel | Buy |
| Jul-03-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-18 | Upgrade | Goldman | Neutral → Buy |
| Mar-07-18 | Upgrade | SunTrust | Hold → Buy |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
View All
Iqvia Holdings Inc Stock (IQV) Latest News
IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes - Financial Times
Can IQVIA Holdings Inc. weather a recessionFed Meeting & Free Expert Approved Momentum Trade Ideas - thegnnews.com
Is IQVIA Holdings Inc. in a consolidation phaseWeekly Gains Report & Weekly Watchlist for Consistent Profits - thegnnews.com
At US$189, Is It Time To Put IQVIA Holdings Inc. (NYSE:IQV) On Your Watch List? - 富途牛牛
Short Interest Drops in IQVIA Holdings Inc. After Rally2025 Market Sentiment & Technical Analysis for Trade Confirmation - sundaytimes.kr
IQVIA’s SWOT analysis: healthcare analytics leader faces market headwinds - Investing.com
Stock Analysis | IQVIA OutlookMixed Signals Amid Market Volatility - AInvest
Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term - Yahoo Finance
Positive Outlook for Narrow-Moat Iqvia Thanks to Durable Customer Demand and Solid Execution - Morningstar
IQVIA Holdings Inc. Shows Early Signs of Technical StrengthJuly 2025 Recap & Fast Exit and Entry Strategy Plans - beatles.ru
IQVIA Surges 2.32% as Institutional Jitters Clash with Bullish Analysts and 392nd Volume Rank - AInvest
Fund Update: Clarkston Capital Partners, LLC added 237,975 shares of IQVIA HOLDINGS ($IQV) to their portfolio - Quiver Quantitative
IQVIA Surges 3.23% as Strategic Partnership with Kexing Biopharm Drives $270M Volume Spike Ranks 395th in Daily Trading Activity - AInvest
IQVIA Holdings Forms Strategic Partnership with Kexing Biopharm to Enhance Global Drug Development Efforts - AInvest
IQVIA Holdings (IQV) Enters Partnership With Kexing Biopharm To Enhance Drug Development - Yahoo Finance
Kexing Biopharm Partners with IQVIA for Global Clinical Development and Commercialization. - AInvest
Kexing Biopharm enters strategic partnership with IQVIA - MarketScreener
What to Expect From IQVIA Holdings' Q2 2025 Earnings Report - MSN
Is IQVIA Holdings Inc. gaining market shareAggressive Growth Portfolio - thegnnews.com
Resistance Break Could Fuel IQVIA Holdings Inc. RallyShort Term Trading Opportunity Watch Sees Shift - beatles.ru
IQVIA Holdings Inc. Share Price Analysis: Growth and Valuation - AInvest
IQVIA Holdings Inc. Uptrend in Early Stages Indicators Say YesWeekly Watchlist of High Movers Released - beatles.ru
What are analysts’ price targets for IQVIA Holdings Inc. in the next 12 monthsAchieve fast wealth growth with smart picks - Jammu Links News
How does IQVIA Holdings Inc. compare to its industry peersUnstoppable investment returns - Jammu Links News
What is IQVIA Holdings Inc. company’s growth strategyHigh-yield capital appreciation - Jammu Links News
What are the technical indicators suggesting about IQVIA Holdings Inc.Discover high-growth stocks for your portfolio - Jammu Links News
Is IQVIA Holdings Inc. stock overvalued or undervaluedConsistently superior profits - Jammu Links News
What are IQVIA Holdings Inc. company’s key revenue driversFree Trend-Following Techniques - Jammu Links News
Why is IQVIA Holdings Inc. stock attracting strong analyst attentionExponentially increasing returns - Jammu Links News
What are the latest earnings results for IQVIA Holdings Inc.Capitalize on emerging market trends - Jammu Links News
What catalysts could drive IQVIA Holdings Inc. stock higher in 2025Unprecedented profit potential - Jammu Links News
What analysts say about IQVIA Holdings Inc. stockHigh-yield capital appreciation - Jammu Links News
IQVIA Holdings Inc. (NYSE:IQV) Position Boosted by CVA Family Office LLC - 富途牛牛
What markets is IQVIA Holdings Inc. expanding into Is SGLY stock a good long term investment optionRemarkably fast returns - Jammu Links News
Is IQVIA Holdings Inc. a growth stock or a value stockDiscover market opportunities with real-time data - Jammu Links News
What is the risk reward ratio of investing in IQVIA Holdings Inc. stockCapitalize on market trends with confidence - Jammu Links News
Is IQVIA Holdings Inc. a good long term investmentOutstanding investment returns - Jammu Links News
IQVIA’s Stock Lags While Long-Term Prospects Take Shape - Finimize
What is the dividend policy of IQVIA Holdings Inc. stockAdvanced Screener Ideas For Every Investor - jammulinksnews.com
IQVIA Holdings (NYSE:IQV) Sheds 4.7% This Week, as Yearly Returns Fall More in Line With Earnings Growth - 富途牛牛
IQVIA's 419th-Ranked Liquidity Amid Institutional Bullishness and Insider Selling Spree - AInvest
Understanding IQVIA Holdings' ROE: A Key to Unlocking Company Performance - AInvest
Why IQVIA Holdings Inc. (NYSE:IQV) Looks Like A Quality Company - Yahoo Finance
Verisk Earnings & Revenues Surpass Estimates in Q2, Increase Y/Y - The Globe and Mail
Deutsche Bank Remains a Buy on IQVIA Holdings (IQV) - The Globe and Mail
Stifel Nicolaus Maintains Buy Rating on IQVIA Holdings with $234 Price Target - AInvest
Price Channel Expanding on IQVIA Holdings Inc.’s ChartTop Performing Stock Insights Released Daily - metal.it
Fiserv Q2 Earnings Beat Estimates on Strong Margins, Revenues Miss - The Globe and Mail
Stifel Nicolaus Remains a Buy on IQVIA Holdings (IQV) - The Globe and Mail
5 Revealing Analyst Questions From IQVIA’s Q2 Earnings Call - Yahoo Finance
How strong is IQVIA Holdings Inc. company’s balance sheetBest Dividend Report With High Returns - jammulinksnews.com
Iqvia Holdings Inc Stock (IQV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.88%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):